Opportunity remains despite regulatory and access obstacles.
Karina Ikeda
Advertisement
Karina Ikeda is a senior consultant within the life sciences practice at Guidehouse
Articles by Karina Ikeda
Advertisement
Latest Updated Articles
The JAKs Journey Offers Valuable Lessons for InnovatorsFebruary 17th 2022
Advertisement
Advertisement
Trending on PharmExec
1
Pharmaceutical Executive Daily: FDA Votes 10 to 3 in Favor of Replimune's Rp1 Efficacy Data
2
Why Real-Time Data Analytics Are Vital for the Next Evolution of Clinical Trials
3
Funding Roundup: Braveheart, Attovia, Vogenx All Announce IPO’s
4
Replimune Shares Crash Following FDA Review of Melanoma Treatment
5